v3.25.1
STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 29, 2025
Equity [Abstract]  
SCHEDULE OF NON-VESTED RESTRICTED STOCK ACTIVITY

Restricted stock activity for the three month period ended March 29, 2025 was as follows:

 

   Shares   Weighted Average
Grant Fair Value		   Fair
Value		   Intrinsic Value 
Non-vested at December 28, 2024   4,833,611   $1.19   $5,757,391   $6,718,720 
Granted   1,634,864    1.32   $2,158,020    - 
Forfeited   (150,805)   1.26   $(190,014)   - 
Non-vested at March 29, 2025   6,317,670   $1.22   $7,725,397   $6,002,418 
Expected to vest   6,317,670                
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock and stock options awards for the three months ended March 29, 2025 and March 30, 2024 (no tax benefits were recognized):

 

   Three Months
Ended		   Three Months
Ended		 
   March 29, 2025   March 30, 2024 
Cost of product revenues  $139,437   $220,605 
Research and development   117,720    143,823 
Selling, general and administrative   517,235    370,500 
Total  $774,392   $734,928 
SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS

 

   Three Months
Ended		 
   March 29, 2025 
Average risk-free interest rate   4.54%
Expected dividend yield   None 
Expected life (average, in years)   8.00 
Expected volatility   85.00%
Weighted average exercise price  $1.76 
Weighted average fair value  $1.16 
SCHEDULE OF STOCK OPTION ACTIVITY

A summary of stock option activity for the period ended March 29, 2025 is as follows:

 

   Number of Options   Weighted Average Exercise Price   Intrinsic Value 
Outstanding as of December 28, 2024   —   $—   $— 
Granted   591,366   $1.76      
Outstanding as of March 29, 2025   591,366   $1.76   $— 
Options exercisable as of December 28, 2024   —   $—   $— 
Options exercisable as of March 29, 2025   591,366   $1.76   $—